Cancer Drugs

Latest Headlines

Latest Headlines

Peptide shells provide a targeted cancer drug delivery system

Scientists coated nanospheres of paclitaxel with a peptide shell that stays intact as it travels through the circulatory system and is then split open by enzymes known to spur metastasis. The drug can then be directed straight to cancer cells at 16 times the regular dose, halting tumor growth.

Takeda hands in its Velcade successor with blockbuster ambitions

Japanese drugmaker Takeda is angling to win FDA approval for its lead cancer asset, an oral treatment for blood malignancies that is key to the company's future in oncology.

Agios' top cancer drug notches more remissions on the way to Phase III

Agios Pharmaceuticals' lead cancer drug extended its streak of promising clinical results, racking up remissions in an expanded Phase I trial as the company prepares for late-stage testing.

Winship research team flags potential of a new lung cancer therapy

Investigators at the Winship Cancer Institute at Emory University say they've found a new molecule that appeared to do better than an inhibitor in preclinical in vivo testing.

Bayer hits the gas on its top cancer prospect with Phase III in sight

Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.

Termeer helps Aura bag $21M to mount a nanosized attack on eye cancers

Upstart cancer drug developer Aura Biosciences has rounded up $21 million for its Series B, attracting a large group of backers and keeping former Genzyme CEO and ubiquitous biotech investor Henri Termeer in the game.

Scripps investigators ID a key player in disarming chemotherapy

Multidrug resistance to the chemotherapies in wide use today is a lethal problem. As patients stop responding to drugs, they become increasingly vulnerable to a deadly assault. Now investigators at The Scripps Research Institute say they have illuminated a key protein that plays a big role in promoting drug resistance, offering a new approach for investigators designing the next generation of new and improved cancer therapies that won't eventually be disarmed.

G1 banks $33M to cut in on a blockbuster oncology race

North Carolina's G1 Therapeutics hauled in $33 million to advance a headline-grabbing approach to cancer treatment, helping the biotech hit the gas in a space otherwise dominated by Big Pharma.

MicroRNA holds clues to predicting progression-free myeloma survival

A group of scientists at Dana-Farber Cancer Institute say they may have a lead on a pair of biomarkers that could help predict the likelihood of extending progression-free survival in multiple myeloma patients. And their work may help guide the development of future treatments.

UPDATED: Kite Pharma spikes on its second take of CAR-T cancer study

Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.